Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

MYL : 29.26 (-0.31%)
IRWD : 13.40 (+2.84%)
AZN : 35.79 (-0.89%)
AGN : 152.89 (+0.13%)
What's in Store for Merck in 2019 After a Solid Run in '18?

Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
INCY : 76.56 (-2.79%)
AMGN : 198.89 (-0.25%)
Moderna (MRNA) Announces Pipeline Progress, Shares Rise

Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
VRTX : 186.15 (-0.28%)
MRNA : 16.26 (-1.99%)
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

IRWD : 13.40 (+2.84%)
AZN : 35.79 (-0.89%)
AGN : 152.89 (+0.13%)
TAK : 19.50 (-2.84%)
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
PJP : 65.43 (-0.86%)
IHE : 145.72 (-0.53%)
PPH : 57.08 (-0.44%)
PFE : 42.11 (-1.45%)
Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2

TOKYO and LONDON, January 7, 2019 /PRNewswire/ --

AZN : 35.79 (-0.89%)
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate

Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.

CELG : 87.30 (-1.05%)
AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
LLY : 116.80 (-0.25%)
ABBV : 85.55 (+0.06%)
PFE : 42.11 (-1.45%)
BMY : 49.13 (-1.19%)
Why the Earnings Surprise Streak Could Continue for Astrazeneca (AZN)

Astrazeneca (AZN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AZN : 35.79 (-0.89%)
Immunomedics Enters Into Supply Deal for Breast Cancer Drug

Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.

AZN : 35.79 (-0.89%)
CLVS : 22.72 (-2.53%)
IMMU : 17.83 (-1.05%)
BMY : 49.13 (-1.19%)
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019

J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug...

AZN : 35.79 (-0.89%)
JNJ : 128.04 (-1.02%)
MRK : 74.61 (+0.15%)
LLY : 116.80 (-0.25%)
NVS : 87.95 (+0.09%)
The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca

The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca

AZN : 35.79 (-0.89%)
PG : 91.37 (-0.70%)
ORCL : 48.06 (-0.66%)
UPS : 96.99 (-0.58%)
FDX : 171.36 (+0.43%)
Top Research Reports for Procter & Gamble, Oracle & United Parcel Service

Top Research Reports for Procter & Gamble, Oracle & United Parcel Service

AZN : 35.79 (-0.89%)
PG : 91.37 (-0.70%)
SLB : 41.25 (-1.13%)
UPS : 96.99 (-0.58%)
ORCL : 48.06 (-0.66%)
FDX : 171.36 (+0.43%)
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations

Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
JNJ : 128.04 (-1.02%)
LLY : 116.80 (-0.25%)
PFE : 42.11 (-1.45%)
GSK : 38.41 (-1.64%)
BMY : 49.13 (-1.19%)
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting

AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
CLVS : 22.72 (-2.53%)
TSRO : 74.88 (+0.03%)
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base

Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.

ITGR : 80.57 (+1.56%)
AZN : 35.79 (-0.89%)
MYGN : 28.22 (-3.82%)
VEEV : 101.67 (+0.27%)
Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia

--ROCKIES demonstrated a statistically-significant improvement in hemoglobin vs. epoetin alfa in dialysis-dependent patients

AZN : 35.79 (-0.89%)
LYNPARZA(R) (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

--First PARP inhibitor approved in 1st-line maintenance for BRCAm advanced ovarian cancer

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
BMY vs. AZN: Which Stock Should Value Investors Buy Now?

BMY vs. AZN: Which Stock Is the Better Value Option?

AZN : 35.79 (-0.89%)
BMY : 49.13 (-1.19%)
Merck to Acquire Europe's Antelliq Group for $2.4 Billion

Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.

AZN : 35.79 (-0.89%)
MRK : 74.61 (+0.15%)
LLY : 116.80 (-0.25%)
BMY : 49.13 (-1.19%)
Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an...

AZN : 35.79 (-0.89%)

Van Meerten Stock Picks

Xilinx - Nasdaq 100 pick
My NASDAQ 100 Pick of the Day belongs to the semiconductor company Xilinx(XLNX).
XLNX -0.72
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar